Research from the National Institutes of Health have identified a process that may help explain why GLP-1 medications work exceptionally well for some people, less effectively for others, and often become less powerful over time.
What has remained less clear is how these drugs influence the internal machinery of the neurons they target.
According to NIH researcher Andrew Lutas, scientists have had only a limited understanding of the biological events taking place within these cells after a GLP-1 drug is introduced.
The study was led by Claire Gao, a postdoctoral researcher at NIH’s National Institute of General Medical Sciences.
Using advanced fluorescence imaging, the team observed living mouse brain tissue and monitored how semaglutide affected individual neurons.
Researchers also selectively blocked or removed certain signaling molecules to identify which pathways were most important for the drug’s weight-loss-related effects.
The results pointed to one key player: a signaling molecule called cyclic adenosine monophosphate, better known as cAMP.
The Role of cAMP in GLP-1 Drug Response
Scientists found that semaglutide increased cAMP activity in the area postrema, a region of the brain that helps regulate appetite and feeding behavior.
However, not all neurons reacted in the same way.
Some cells showed strong and long-lasting increases in cAMP, while others produced weaker or shorter-lived responses.
Researchers described the effect as a spectrum rather than a simple on-or-off reaction.
This variation could help explain why people often experience different levels of success when taking GLP-1 medications.
Why Weight Loss Can Slow Down
One of the study’s most interesting discoveries involved the fading response seen in certain neurons.
Researchers believe some cells may become less sensitive over time by reducing the number of available GLP-1 receptors or pulling those receptors inside the cell, making them less accessible to the drug.
This process could contribute to the weight-loss plateaus that many patients report after months of treatment.
The findings suggest that changes inside brain cells may play a role in the gradual decline in effectiveness seen with some GLP-1 therapies.
Can Future Treatments Last Longer?
The team also explored ways to extend the drug’s cellular effects.
By using roflumilast, a medication that blocks the enzyme PDE4, researchers were able to keep cAMP levels elevated in a larger number of neurons for longer periods.
Although the work is still in its early stages, the results raise intriguing possibilities.
Future treatments could potentially maintain their effectiveness longer, reduce the need for frequent dosing, or help patients continue losing weight after reaching a plateau.
Researchers emphasize that these ideas remain theoretical for now and will require much more investigation.
The study had one major limitation: Scientists could only monitor signaling activity in brain tissue for a few hours.
Future research will focus on developing techniques that allow researchers to follow these cellular changes over days, weeks, or even longer periods.
